![](/img/cover-not-exists.png)
monarcHER: A phase 2 randomized open-label study of abemaciclib plus trastuzumab (T) with or without fulvestrant (F) compared to standard-of-care chemotherapy of physician's choice plus T in women with HR + , HER2+ advanced breast cancer
Tolaney, S.M., Bourayou, N., Goel, S., Forrester, T., André, F.Volume:
27
Language:
english
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdw365.93
Date:
October, 2016
File:
PDF, 39 KB
english, 2016